Despite potential short-cuts, drug development is a lengthy and risky process that culminates in marketing approval. However, just because a drug achieves regulatory approval, does not mean that it will be instantly available to those in need. […]
It can be difficult for public health insurers to decide which medical interventions to cover. After all, it is the tax payers’ money that must be spent wisely and equitably across all patient groups.
Transgender health management has seen important advances in the recent past. Some notable remaining issues revolve around the standard of care and insurance coverage.